HPC Biosciences Ltd Financials
Company Logo

HPC Biosciences Ltd Financial Statement

HPC Biosciences Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2020
Revenue0.85
Operating Expense0.28
Net Profit0.25
Net Profit Margin29.41
Earning Per Share0.02
EBIDTA0.57
Effective Tax Rate3.51

HPC Biosciences Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2021
Total Revenue Annual2.29
Operating Expenses Annual0.67
Operating Profit Annual1.70
Interest AnnualTBA
Depreciation0.51
Net Profit Annual1.17
Tax Annual0.02

HPC Biosciences Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2021
Cash Flow at the Beginning0.30
Cash Flow from Operations1.36
Cash Flow from Investing0.06
Cash Flow from FinancingTBA
Cash Flow at the End1.72

HPC Biosciences Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2021
PBDIT Margin (%)74.24
PBIT Margin (%)51.97
PBT Margin (%)51.97
Net PROFIT Margin (%)51.09
Return On Networth / Equity (%)3.63
Return On Networth /Employed (%)3.69
Return On Assets (%)3.58
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)0.07

HPC Biosciences Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2021
Fixed Assets Annual3.07
Total Current Assets Annual26.07
Non Current Assets Annual7.06
Total Shareholders Funds Annual32.85
Total Assets Annual33.13

HPC Biosciences Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Oct 18, 2024, HPC Biosciences Ltd has a market capitalization of - Cr. Value Research classifies it as a Micro-Cap company.
Yes, HPC Biosciences Ltd is debt-free with a debt-to-equity ratio of 0.00.
In FY 2023 , HPC Biosciences Ltd recorded a total revenue of approximately 0.21 Cr marking a significant milestone in the company's financial performance.
HPC Biosciences Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately NaN% and -1.2% annually, respectively..
HPC Biosciences Ltd's current PE ratio is undefined.
HPC Biosciences Ltd's ROCE averaged 0.7% from the FY ending March 2021 to 2023, with a median of 0.1%. It peaked at 3.6% in March 2021, reflecting strong capital efficiency over the period..
HPC Biosciences Ltd's latest EBIT is Rs. 0.03 Cr, surpassing the average EBIT of Rs. 0.25 Cr over the 5 years..